AUTH/2996/12/17: Pharmacist v Seqirus — Fluad promotional email and “new guidance/policy change” wording (No breach)

📅 2017 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2996/12/17
ComplainantCCG lead prescribing support pharmacist
CompanySeqirus UK Limited
ProductFluad (influenza vaccine, adjuvanted)
MaterialPromotional email (ref UK/FLUD/0917/0026c)
Date sent11 December 2017
Core allegationEmail misleadingly implied JCVI changed recommendations so Fluad should be used for everyone over 65; misleading cost-effectiveness/budget impact; most cost-effective in over 75s
Authority clauses considered7.2, 7.3, 7.4, 9.1, 10.2
OutcomeNo breach
Complaint received14 December 2017
Case completed10 May 2018
Applicable Code year2016
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A CCG lead prescribing support pharmacist complained about a Seqirus UK promotional email for Fluad (influenza vaccine, adjuvanted) (ref UK/FLUD/0917/0026c), sent 11 December 2017, subject line “New guidance issued on adult flu vaccines”.
  • The email included a prominent box: “Important: Influenza vaccine policy change affecting your order for 2018/19”.
  • The complainant alleged the email implied JCVI had changed recommendations so Fluad should be used for everyone aged over 65, and that readers might assume a national policy change unless they “delved deeper”.
  • The complainant also alleged the email was misleading on cost-effectiveness and budget impact, and that evidence suggested Fluad was most cost-effective in those aged over 75.
  • Seqirus said the email was based on the draft JCVI October 2017 meeting minutes and the NHS Green Book (updated 1 December 2017), and that quotations were clearly sourced and faithfully reproduced.
⚖️

Outcome

  • No breach of the Code was ruled.
  • The Panel considered the email made clear throughout that quotations were from a draft JCVI minute, and that describing the subject as a “policy change” was not unreasonable given the Green Book reflected the draft minute.
  • The Panel did not consider the complainant had established the email was misleading regarding comparative effectiveness/cost-effectiveness or budget implications as alleged.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training